Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA) - PubMed
7 days ago
- #real-world-study
- #tofacitinib
- #rheumatoid-arthritis
- Study focused on tofacitinib in rheumatoid arthritis (RA) in a real-world German setting (ESCALATE-RA).
- Primary outcomes included predictors of treatment changes, effectiveness, and patient-reported outcomes (PROs).
- Key factors for treatment changes were 'lack of efficacy' (HR 3.30) and 'intolerance' (HR 4.43).
- Higher patient satisfaction reduced likelihood of treatment changes (HR 0.82).
- Increased glucocorticoid (GC) doses raised probability of step-up/switch changes (HR 1.21).
- Tofacitinib drug survival was 48% at study end.
- Significant improvements in disease activity (low disease activity: Δ62%, remission: SDAI Δ25%, CDAI Δ28%).
- Reduction in mean concomitant GC dose (2 mg/day).
- PROs showed reduced pain and fatigue, improved functional ability and quality of life.
- 63.9% experienced treatment-emergent adverse events (AEs), 8.8% had AEs of special interest, 0.5% deaths.
- Safety profile consistent with known tofacitinib data.